Navigation Links
CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
Date:5/20/2009

SAN MARINO, Calif., May 20 /PRNewswire-FirstCall/ -- On April 16, 2009 and March 18, 2009, biotechnology firm Viral Genetics, Inc. (Pink Sheets: VRAL) announced "that the company is pursing a promising new therapy for Lyme Disease with funding from Time for Lyme, Inc., and the Turn Corner Foundation." This correction is to clarify that those grants were not made to Viral Genetics but were made directly to the University of Colorado where Dr. M. Karen Newell is a tenured professor. The University then applied the funds to promising research into a treatment for Lyme Disease that is being conducted by Dr. M. Karen Newell and her research group at the University of Colorado. Any inference in the press releases that the grants were made directly to Viral Genetics rather than the university is incorrect.

Viral Genetics has certain exclusive licenses and options from the University of Colorado under previously filed patent rights, the work by Dr. Karen. Viral Genetics' license with the University is in return for certain obligations and fees.

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). The company recently entered into an exclusive license agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. For more information, visit www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC and after March 25, 2009, filed on the pink sheets web site. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

    Viral Genetics
    Haig Keledjian, 626-334-5310


'/>"/>
SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Correction: Lawrence County Raw Milk Dairy Tests Negative for Campylobacter; Raw Milk Sales Resumed
2. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
3. Correction: Evalve Announces CE Mark Approval of the Worlds First Percutaneous Valve Repair System
4. Correction: Therapist to Young Hollywood Says Male Stars in Psychological Trouble Get a Media Pass as Compared to Female Stars
5. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
6. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
7. National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action
8. Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
9. World Health Assembly Forced to Postpone Decision on Viral Hepatitis
10. Viral Infection Might Trigger High Blood Pressure
11. Veterinarians at high risk for viral, bacterial infections from animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... technology-enabled services supporting clinical research, today announces that 30 of its domain ... the drug development lifecycle at upcoming industry conferences and webinars. Drawing on ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings ... shop for the hottest Korean cosmetics and fashion trends sweeping the nation. The decision ... already well-known for the great offerings that allow Koreans everywhere to look their best ...
(Date:9/25/2017)... , ... September 25, 2017 , ... “The Majestic Unicorn”: ... the great flood. “The Majestic Unicorn” is the creation of published author, Dayna Chantel, ... small, came from far and wide to march aboard the cypress ark-vessel. Male and ...
(Date:9/25/2017)... Philadelphia, PA (PRWEB) , ... September 25, 2017 , ... Emerald Ash Borers ... pest's destruction can be seen throughout the Philadelphia region. A video by Rob Nagy, ... is lined with Ash trees. While several are dead or showing signs of decline ...
(Date:9/24/2017)... ... ... Throughout the United States and the world, clinicians take a simple but ... providers work to give the best care possible to patients and communities, while seeking ... are threatening to tie our hands in carrying out that oath. The Graham-Cassidy legislation ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017 ... coming to Washington DC ... Tuesday, September 12 th – Monday, September 18 th .The Brain ... MRI brain scans to the public.Where:  BTF,s Mobile ... 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... -- For nearly two decades, New Life Agency has been committed to providing ... New Life Agency announces a powerful three-way partnership designed to deliver substantial ... ... http://www.schrafts2.com/ ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: